Immunobiology of acute graft-versus-host disease

被引:214
作者
Reddy, P
Ferrara, JLM
机构
[1] Univ Michigan, Ctr Canc, Dept Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Ctr Canc, Dept Pediat, Ann Arbor, MI 48109 USA
关键词
Th1; Th2; cytokines; APC; NK cells; CTL;
D O I
10.1016/S0268-960X(03)00009-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of allogeneic bone marrow transplantation (BMT). The immunobiology of acute GVHD is complex and can be conceptualized to be a three-step process. In step 1, the conditioning regimen (irradiation and/or chemotherapy) leads to the damage and activation of host tissues and induces the secretion of inflammatory cytokines TNF-alpha and IL-1. As a consequence expression of MHC antigens and adhesion molecules is increased, thus enhancing the recognition of host alloantigens by donor T cells. Donor T-cell activation in step 2 is characterized by donor T-cell interaction with host APCs and subsequent proliferation, differentiation, and secretion of cytokines. Cytokines such as IL-2 and IFN-gamma enhance T-cell expansion, induce cytotoxic T cells (CTL) and natural killer (NK) cell responses, and prime additional mononuclear phagocytes to produce TNF-alpha and IL-1. These inflammatory cytokines in turn stimulate production of inflammatory chemokines, thus recruiting effector cells into target organs. In step 3, effector functions of mononuclear phagocytes are triggered via a secondary signal provided by lipopolysaccharide (LPS) that leaks through the intestinal mucosa damaged during step 1. This mechanism may result in the amplification of local tissue injury and further promotion of an inflammatory response, which, together with the CTL and NK components, leads to target tissue destruction in the transplant host. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 117 条
[1]   INTERLEUKIN-1 IS A CRITICAL EFFECTOR MOLECULE DURING CYTOKINE DYSREGULATION IN GRAFT-VERSUS-HOST DISEASE TO MINOR HISTOCOMPATIBILITY ANTIGENS [J].
ABHYANKAR, S ;
GILLILAND, DG ;
FERRARA, JLM .
TRANSPLANTATION, 1993, 56 (06) :1518-1523
[2]   Toll-like receptors: critical proteins linking innate and acquired immunity [J].
Akira, S ;
Takeda, K ;
Kaisho, T .
NATURE IMMUNOLOGY, 2001, 2 (08) :675-680
[3]   A PHASE-I PHASE-II STUDY EVALUATING THE MURINE ANTI-IL-2 RECEPTOR ANTIBODY-2A3 FOR TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE [J].
ANASETTI, C ;
MARTIN, PJ ;
HANSEN, JA ;
APPELBAUM, FR ;
BEATTY, PG ;
DONEY, K ;
HARKONEN, S ;
JACKSON, A ;
REICHERT, T ;
STEWART, P ;
STORB, R ;
SULLIVAN, KM ;
THOMAS, ED ;
WARNER, N ;
WITHERSPOON, RP .
TRANSPLANTATION, 1990, 50 (01) :49-54
[4]  
ANTIN JH, 1992, BLOOD, V80, P2964
[5]   Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation [J].
Antin, JH ;
Weisdorf, D ;
Neuberg, D ;
Nicklow, R ;
Clouthier, S ;
Lee, SJ ;
Alyea, E ;
McGarigle, C ;
Blazar, BR ;
Sonis, S ;
Soiffer, RJ ;
Ferrara, JLM .
BLOOD, 2002, 100 (10) :3479-3483
[6]   Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation [J].
Asai, O ;
Longo, DL ;
Tian, ZG ;
Hornung, RL ;
Taub, DD ;
Ruscetti, FW ;
Murphy, WJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (09) :1835-1842
[7]  
ATKINSON K, 1991, BLOOD, V77, P1376
[8]   The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice [J].
Baker, MB ;
Altman, NH ;
Podack, ER ;
Levy, RB .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2645-2656
[9]  
BELANGER C, 1993, BONE MARROW TRANSPL, V11, P293
[10]   INTERLEUKIN-10 ADMINISTRATION DECREASES SURVIVAL IN MURINE RECIPIENTS OF MAJOR HISTOCOMPATIBILITY COMPLEX DISPARATE DONOR BONE-MARROW GRAFTS [J].
BLAZAR, BR ;
TAYLOR, PA ;
SMITH, S ;
VALLERA, DA .
BLOOD, 1995, 85 (03) :842-851